MedTrace Logo

SWITCH: Stentrode First-in-Human Study of Implantable BCI for Control of a Digital Device

NCT03834857 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-09-01

No results posted yet for this study

Summary

SWITCH Study

Conditions

  • Neurologic Disorder

Interventions

DEVICE

Stentrode

Implantation of Stentrode device

Sponsors & Collaborators

  • Synchron Australia Pty Ltd.

    lead INDUSTRY

Principal Investigators

  • Thomas Oxley · University of Melbourne and Synchron

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-27
Primary Completion
2021-12-10
Completion
2022-01-09

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834857 on ClinicalTrials.gov